Targeting survivin in cancer : patent review

Kanwar, Jagat R., Kamalapuram, Sishir K. and Kanwar, Rupinder K. 2010, Targeting survivin in cancer : patent review, Expert opinion on therapeutic patents, vol. 20, no. 12, pp. 1723-1737, doi: 10.1517/13543776.2010.533657.

Attached Files
Name Description MIMEType Size Downloads

Title Targeting survivin in cancer : patent review
Alternative title Review : Targeting survivin in cancer : patent review
Author(s) Kanwar, Jagat R.ORCID iD for Kanwar, Jagat R.
Kamalapuram, Sishir K.
Kanwar, Rupinder K.
Journal name Expert opinion on therapeutic patents
Volume number 20
Issue number 12
Start page 1723
End page 1737
Total pages 15
Publisher Informa Healthcare
Place of publication London, England
Publication date 2010-12
ISSN 1354-3776
Keyword(s) angiogenesis
Summary Importanceof the field: Survivin is a prominent anti-apoptotic molecule expressed widely in the majority of cancers. Overexpression of survivin leads to uncontrolled cancer cell growth and drug resistance. Efficient downregulation of survivin expression and its functions can sensitise the tumour cells to various therapeutic interventions such as chemotherapeutic agents leading to cell apoptosis.

Areas covered in this review: The article thoroughly analyses up-to-date information on the knowledge generated from the survivin patents. Various key areas of research in terms of understanding survivin biology and its targeting are discussed in detail.

What the reader will gain: The article clearly gives an insight on the recent developments undertaken to understand the roles of survivin in cancer and in validating various treatment paradigms that suppress survivin expression in cancer cells.

Take home message:  Most recent developments are helpful for effectively downregulating survivin expression by using various therapeutic platforms such as chemotherapeutic drugs, immunotechnology, antisense, dominant negative survivin mutant, RNA interference and peptide-based methods. However, selective and specific targeting of survivin in cancer cells still poses a major challenge. Nanotechnology-based platforms are currently under development to enable site-specific targeting of survivin in tumour cells.
Language eng
DOI 10.1517/13543776.2010.533657
Field of Research 060199 Biochemistry and Cell Biology not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2010
Copyright notice ©2010, Informa UK, Ltd.
Persistent URL

Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 39 times in TR Web of Science
Scopus Citation Count Cited 42 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 868 Abstract Views, 9 File Downloads  -  Detailed Statistics
Created: Thu, 09 Dec 2010, 09:14:59 EST by Kislay Roy

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact